NCT05900882View on ClinicalTrials.gov

SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease

PHASE2RecruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

July 15, 2022

Primary Completion Date

August 30, 2025

Study Completion Date

August 30, 2025

Conditions
Multiple Myeloma
Interventions
DRUG

Selinexor

Selinexor 60 mg/day, orally on d1,8,15,22

DRUG

Bortezomib

Bortezomib 1.3mg/m2 intravenously on d1,8,15,22

DRUG

Lenalidomide

Lenalidomide 25 mg/d (the dose will be adjusted according to creatinine clearance)

DRUG

Dexamethasone

Dexamethasone 20 mg/day orally on d1-2, d8-9,d15-16,d22-23

Trial Locations (6)

210000

NOT_YET_RECRUITING

Nanjing First People's Hospital, Nanjing

210029

RECRUITING

The First Affiliated Hospital of Nanjing Medical University, Nanjing

213000

NOT_YET_RECRUITING

Changzhou Second People's Hospital, Changzhou

224006

NOT_YET_RECRUITING

Yancheng First People's Hospital, Yancheng

225300

NOT_YET_RECRUITING

Taizhou People's Hospital, Taizhou

226001

NOT_YET_RECRUITING

Affiliated Hospital of Nantong University, Nantong

All Listed Sponsors
lead

The First Affiliated Hospital with Nanjing Medical University

OTHER